INVEGA SUSTENNA® is approved for the treatment of schizoaffective disorder
INVEGA SUSTENNA® Prolactin Elevations and Potentially Prolactin-Related Events
†Prolactin adverse reaction reports among all patients in the double-blind phase, regardless of baseline prolactin levels.
‡In the INVEGA SUSTENNA® group, 2 females reported amenorrhea,1 reported galactorrhea, and 1 reported irregular menstruation, while in the placebo group, 1 female reported amenorrhea and 1 reported breast pain.
§In the INVEGA SUSTENNA® group, 1 male reported erectile dysfunction and in the placebo group, 1 male reported gynecomastia.
Amenorrhea (2.5%) in females and no single potentially prolactin-related adverse reaction in males were observed with a rate >2%.
As with other drugs that antagonize dopamine D2 receptors, INVEGA SUSTENNA® elevates prolactin levels, and the elevation persists during chronic administration. Paliperidone has a prolactin-elevating effect similar to risperidone, which is associated with higher levels of prolactin elevation than other antipsychotic agents.1
References: 1. INVEGA SUSTENNA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2018. 2. Data on file. Janssen Pharmaceuticals, Inc., Titusville, NJ.
Content area 1.2